Yıl: 2020 Cilt: 30 Sayı: 3 Sayfa Aralığı: 180 - 189 Metin Dili: İngilizce DOI: 10.4999/uhod.204622 İndeks Tarihi: 21-12-2020

Does Consolidation Chemotherapy improve Patient Survival in Locally Advanced Non-Small-Cell Lung Cancer?

Öz:
The role of consolidation chemotherapy is being investigated due to inconclusive outcomes, ascribed to high rates of recurrenceand mortality with standard concurrent chemoradiotherapy (CRT) in patients with unresectable locally advanced non-small-cell lungcancer (LA-NSCLC). We evaluated the impact of consolidation chemotherapy on the survival of patients with LA-NSCLC at our singlemedical centre. In total, 136 patients with unresected LA-NSCLC were evaluated to identify and compare the factors influencingsurvival rates. The median overall survival (OS) was 27 and 23.6 months and median progression-free survival (PFS) was 12.3 and12.8 months in the CRT and consolidation treatment groups (p= 0.840 and 0.808), respectively. Consolidation chemotherapy afterconcurrent CRT experiences has neither OS nor PFS survival benefit, compared with concurrent CRT alone. Thus, our study did notsupport favourable consolidation chemotherapy in patients with LA-NSCLC.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394-424, 2018.
  • 2. Reck M, Rabe KF. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. N Engl J Med 377: 849-861, 2017.
  • 3. Shlomi D, Ben-Avi R, Balmor GR, et al. Screening for lung cancer: time for large-scale screening by chest computed tomography. Eur Respir J 44: 217-238, 2014.
  • 4. Wang X, Ding X, Kong D, et al. The effect of consolidation chemotherapy after concurrent chemoradiotherapy on the survival of patients with locally advanced non-small cell lung cancer: a meta-analysis. Int J Clin Oncol 22: 229-236, 2017.
  • 5. Reich JM. A critical appraisal of overdiagnosis: estimates of its magnitude and implications for lung cancer screening. Thorax 63: 377-383, 2008.
  • 6. Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc 94: 1623-1640, 2019.
  • 7. Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol 8: 1, 2017.
  • 8. O’Rourke N, Figuls MRI, Bernadó NF, Macbeth F. Concurrent chemoradiotherapy in non‐small cell lung cancer. Cochrane Database of Systematic Reviews, 2010.
  • 9. Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer: American College of Chest Physicians evidencebased clinical practice guidelines. Chest 143: e314S-e340S, 2013.
  • 10. Urvay S, Yücel B. Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a retrospective study. Ortadogu Medical Journal/Ortadogu Tip Dergisi 11: 40-46, 2019.
  • 11. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non–small-cell lung cancer: The Hoosier Oncology Group and US Oncology. J Clin Oncol 26: 5755-5760, 2008.
  • 12. Tsujino K, Kurata T, Yamamoto S, et al. Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non–small-cell lung cancer?: A pooled analysis of the literature. J Thorac Oncol 8: 1181-1189, 2013.
  • 13. Goldstraw P, Crowley J, Chanksy K, et al. Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumors. J Thorac Oncol 2: 706– 714, 2007. The above article ran in the August 2007 issue without showing the figures on page 711 in color. We regret any inconvenience this may have caused. In this issue, we present Figures 2 and 3 from that article in full color. J Thorac Oncol 2: 985, 2007.
  • 14. Therasse P, Eisenhauer E, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 42:1031-1039, 2006.
  • 15. Filippi AR, Di Muzio J, Badellino S, et al. Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance? J Thorac Dis 10: S1461, 2018.
  • 16. Eroglu C, Orhan O, Unal D, et al. Concomitant chemoradiotherapy with docetaxel and cisplatin followed by consolidation chemotherapy in locally advanced unresectable nonsmall cell lung cancer. Ann Thorac Med 8: 109, 2013.
  • 17. Harris JP, Patel MI, Loo BW, et al. A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer. Lung Cancer 108: 173-182, 2017.
  • 18. Liu L, Bi N, Ji Z, et al. Consolidation chemotherapy may improve survival for patients with locally advanced non-smallcell lung cancer receiving concurrent chemoradiotherapyretrospective analysis of 203 cases. BMC Cancer 15: 715, 2015.
  • 19. Ahn JS, Ahn YC, Kim JH, et al. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in Inoperable stage III non-small-cell lung cancer: KCSG-LU05-04. J Clin Oncol 33: 2660-2666, 2015.
  • 20. Jalal S, Riggs H, Melnyk A, et al. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Ann Oncol 23: 1730-1738, 2012.
  • 21. Mutlu H, Arslan D, Gündüz S, et al. The optimal treatment modality in patients with T4N2M0 non-small cell lung cancer: the best choice may be definitive chemoradiotherapy followed by consolidation chemotherapy. Chemotherapy 60: 107-111, 2014.
  • 22. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65: 25-32, 1980.
  • 23. Jeremic B. Consolidation chemotherapy after concurrent radiochemotherapy in locally advanced non–small cell lung cancer may have been beneficial if we only knew where it have worked. J Thorac Oncol 9: e7, 2014.
  • 24. Agata E, Adam A. Comorbidities in lung cancer. Pneumonol Alergol Pol 84: 186-192, 2016
  • 25. Ezer N, Smith CB, Galsky MD, et al. Cisplatin vs. carboplatinbased chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer. Radiother Oncol 112: 272-278, 2014.
  • 26. Soo RA, Kawaguchi T, Loh M, et al. Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy. Future Oncology 8: 451-462, 2012.
APA BUĞDAYCI BAŞAL F, ASLAN F, OZGUN G, bilgetekin i, oksuzoglu b, DEMIRCI U (2020). Does Consolidation Chemotherapy improve Patient Survival in Locally Advanced Non-Small-Cell Lung Cancer?. , 180 - 189. 10.4999/uhod.204622
Chicago BUĞDAYCI BAŞAL FATMA,ASLAN FERİT,OZGUN Güliz,bilgetekin irem,oksuzoglu berna,DEMIRCI UMUT Does Consolidation Chemotherapy improve Patient Survival in Locally Advanced Non-Small-Cell Lung Cancer?. (2020): 180 - 189. 10.4999/uhod.204622
MLA BUĞDAYCI BAŞAL FATMA,ASLAN FERİT,OZGUN Güliz,bilgetekin irem,oksuzoglu berna,DEMIRCI UMUT Does Consolidation Chemotherapy improve Patient Survival in Locally Advanced Non-Small-Cell Lung Cancer?. , 2020, ss.180 - 189. 10.4999/uhod.204622
AMA BUĞDAYCI BAŞAL F,ASLAN F,OZGUN G,bilgetekin i,oksuzoglu b,DEMIRCI U Does Consolidation Chemotherapy improve Patient Survival in Locally Advanced Non-Small-Cell Lung Cancer?. . 2020; 180 - 189. 10.4999/uhod.204622
Vancouver BUĞDAYCI BAŞAL F,ASLAN F,OZGUN G,bilgetekin i,oksuzoglu b,DEMIRCI U Does Consolidation Chemotherapy improve Patient Survival in Locally Advanced Non-Small-Cell Lung Cancer?. . 2020; 180 - 189. 10.4999/uhod.204622
IEEE BUĞDAYCI BAŞAL F,ASLAN F,OZGUN G,bilgetekin i,oksuzoglu b,DEMIRCI U "Does Consolidation Chemotherapy improve Patient Survival in Locally Advanced Non-Small-Cell Lung Cancer?." , ss.180 - 189, 2020. 10.4999/uhod.204622
ISNAD BUĞDAYCI BAŞAL, FATMA vd. "Does Consolidation Chemotherapy improve Patient Survival in Locally Advanced Non-Small-Cell Lung Cancer?". (2020), 180-189. https://doi.org/10.4999/uhod.204622
APA BUĞDAYCI BAŞAL F, ASLAN F, OZGUN G, bilgetekin i, oksuzoglu b, DEMIRCI U (2020). Does Consolidation Chemotherapy improve Patient Survival in Locally Advanced Non-Small-Cell Lung Cancer?. Uluslararası Hematoloji-Onkoloji Dergisi, 30(3), 180 - 189. 10.4999/uhod.204622
Chicago BUĞDAYCI BAŞAL FATMA,ASLAN FERİT,OZGUN Güliz,bilgetekin irem,oksuzoglu berna,DEMIRCI UMUT Does Consolidation Chemotherapy improve Patient Survival in Locally Advanced Non-Small-Cell Lung Cancer?. Uluslararası Hematoloji-Onkoloji Dergisi 30, no.3 (2020): 180 - 189. 10.4999/uhod.204622
MLA BUĞDAYCI BAŞAL FATMA,ASLAN FERİT,OZGUN Güliz,bilgetekin irem,oksuzoglu berna,DEMIRCI UMUT Does Consolidation Chemotherapy improve Patient Survival in Locally Advanced Non-Small-Cell Lung Cancer?. Uluslararası Hematoloji-Onkoloji Dergisi, vol.30, no.3, 2020, ss.180 - 189. 10.4999/uhod.204622
AMA BUĞDAYCI BAŞAL F,ASLAN F,OZGUN G,bilgetekin i,oksuzoglu b,DEMIRCI U Does Consolidation Chemotherapy improve Patient Survival in Locally Advanced Non-Small-Cell Lung Cancer?. Uluslararası Hematoloji-Onkoloji Dergisi. 2020; 30(3): 180 - 189. 10.4999/uhod.204622
Vancouver BUĞDAYCI BAŞAL F,ASLAN F,OZGUN G,bilgetekin i,oksuzoglu b,DEMIRCI U Does Consolidation Chemotherapy improve Patient Survival in Locally Advanced Non-Small-Cell Lung Cancer?. Uluslararası Hematoloji-Onkoloji Dergisi. 2020; 30(3): 180 - 189. 10.4999/uhod.204622
IEEE BUĞDAYCI BAŞAL F,ASLAN F,OZGUN G,bilgetekin i,oksuzoglu b,DEMIRCI U "Does Consolidation Chemotherapy improve Patient Survival in Locally Advanced Non-Small-Cell Lung Cancer?." Uluslararası Hematoloji-Onkoloji Dergisi, 30, ss.180 - 189, 2020. 10.4999/uhod.204622
ISNAD BUĞDAYCI BAŞAL, FATMA vd. "Does Consolidation Chemotherapy improve Patient Survival in Locally Advanced Non-Small-Cell Lung Cancer?". Uluslararası Hematoloji-Onkoloji Dergisi 30/3 (2020), 180-189. https://doi.org/10.4999/uhod.204622